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Summary
RNA interference (RNAi) is a sequence-specific gene-silencing mechanism triggered by double-
stranded RNA. RNAi was shown to allow transient or stable knockdown of gene expression in a
broad range of species and has been used successfully for functional genomic screens in mam-
malian cells and Caenorhabditis elegans. Standard therapeutic use of RNAi in clinical settings in
humans has been hampered by the lack of effective methods to deliver the small-interfering
RNAs (siRNAs) or short-hairpin RNA expression vectors into the diseased organs. In mice, sys-
temic delivery of siRNAs by hydrodynamic intravascular injection leads to highly efficient
uptake of siRNAs into the liver. Several groups demonstrated therapeutic use of RNAi in mouse
models of acute liver failure or hepatitis B virus replication. This chapter will focus on the tech-
nical background of hydrodynamic and portal vein delivery techniques in mice and will give
practical guidance for using these techniques for siRNA delivery into the liver. 
Key Words: siRNA; RNA interference; hydrodynamic intravascular injection; apoptosis;
acute liver failure.
1. Introduction 
RNA interference (RNAi) has been shown to be a powerful tool to study
gene function in a broad range of different organisms. It overcomes the lim-
itations of classical genetic methods to knockdown gene expression in
mammalian cells. Most recently, RNAi has been exploited as a high-
throughput genomics tool in mammals (1–3). Furthermore, RNAi holds
great promise as a therapeutic tool. Applications of RNAi directed against
targets in diseases, for example cancer, infectious diseases, or dominant
genetic diseases, are conceivable. Although the therapeutic use in humans is
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still some time from becoming routine in the clinic, use of experimental
delivery methods in mice currently allows the study of RNAi in preclinical
therapeutic settings (4–7).
Because numerous comprehensive reviews about RNAi are available in the
literature, this chapter will not give a detailed background on the discovery of
RNAi but will focus on practical aspects of using RNAi in mice. 
1.1. Efficient Delivery: the Holy Grail of Gene Therapeutic Approaches
The holy grail of all in vivo gene therapeutic approaches is to deliver
effective amounts of the therapeutic gene into the desired target cells.
Currently, viral vectors are most widely used for delivery of therapeutic
genes in vivo. However, vector-associated side effects limit their value as a
tool for clinical use.
Systemic application of plasmid DNA or antisense oligonucleotides
(ASO), however, leads to very low uptake in most tissues. In part, this is
owing to the fact that nucleic acids are rapidly degraded after systemic
intravascular application in vivo. With regard to future therapeutic applica-
tions in humans, it is promising that under certain conditions short-interfering
RNA (siRNA) duplexes seem to be more stable than chemically modified
ASO (8). Several approaches have been described to achieve more efficient
uptake of naked DNA or ASO into tissues in vivo. Among these are direct
injection into the target organ, as shown for muscle and liver (9,10) and 
electroporation (11,12).
1.2. Hydrodynamic Intravascular Injection
The large volume hydrodynamic delivery technique was a major advance in
the in vivo delivery of nucleic acids into mice and rats. In principle, it means
the injection of a high volume into the vascular system within a short period of
time. The first report that this delivery method can be even more effective than
direct injection into the target organ is from Budker et al. (13), who injected
high volumes of either lacZ or luciferase reporter plasmids into the portal vein
of mice. Using this approach approx 1% of all hepatocytes throughout the
whole liver showed uptake of the plasmid. Remarkably, reporter activity was
undetectable in endothelial and bile duct cells. 
Because surgery on mice and intraportal injection is not feasible in every
laboratory, it was an important discovery that injection of a high volume of
plasmid DNA into the tail vein also leads to a very efficient uptake of DNA
into the liver (14). In 2002, McCaffrey et al. showed that the hydrodynamic
tail-vein delivery technique could be used to effectively deliver siRNA into
hepatocytes (15). Subsequent studies showed that the siRNA uptake into the
liver after hydrodynamic tail-vein delivery is much more effective than the
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uptake of plasmid DNA using this technique; uptake of siRNA in up to 70–90%
of all hepatocytes was achieved (16,17). 
The physiological mechanisms of the hydrodynamic intravascular injection
technique are still not fully elucidated. Intravascular delivery of a large bolus of
fluid is thought to result in an accumulation of the liquid in the caval vein. As
the heart is swamped with the high amount of liquid, a temporary right heart
failure with subsequent backflow into the liver is the consequence. In the liver,
the fluid is thought to be extravasated through the pores (fenestrate) in the liver
endothelium (sinusoids). It is well known that liver endothelium has a much
bigger average pore size than endothelium of other organs. The observation that
siRNA uptake into the liver after hydrodynamic tail-vein injection is much
higher than the uptake of plasmid DNA is in line with the idea that extravasa-
tion through the endothelial pores is a prerequisite for uptake into hepatocytes.
After passing the endothelium, the siRNA molecules or plasmid DNA are in
direct contact with the hepatocytes. Whether the molecules are finally internal-
ized by receptor mediated (18) or receptor independent processes like mem-
brane rupture (19) remains unclear.
1.3. Therapeutical Use of siRNA to Prevent 
and Treat Acute Liver Failure in Mice
As the first demonstrations of a therapeutic application of siRNA in vivo
were done in mouse models of acute liver failure (ALF), the next paragraphs
will give a brief introduction into this disease, followed by a discussion of the
therapeutic use of siRNA to suppress apoptosis in this model.
ALF is defined as a dramatic clinical syndrome in which a previously nor-
mal liver fails within days or weeks. Three subgroups of ALF can be distin-
guished, hyperacute, acute, and subacute liver failure. Despite the frequent
occurrence of cerebral edema and renal failure in patients with hyperacute
liver failure, prognosis without transplantation is relatively good. Survival
rates in patients with acute and subacute liver failure, however, are at best
15% (20,21). The etiology of ALF shows marked worldwide variation: in
underdeveloped countries viral causes predominate, whereas drug-induced
hepatotoxicity and seronegative hepatitis predominate in most countries of
the Western world (22). To this day, the management of these varying clinical
scenarios is essentially supportive. It aims to identify and remove the insult
that led to destruction of the liver, whereas preventing associated complica-
tions, such as acute renal and respiratory failure, bleeding diatheses, severe
sepsis, cerebral edema, and encephalopathy. Overall mortality in patients with
severe ALF remains high, ranging from 40 to 80%. Although liver support
devices or hepatocyte transplantation may in time have a place in treatment,
currently liver transplantation remains the only therapeutic option that has
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been shown to significantly improve the outcome of patients with ALF.
Because of limitations of donor organs and the requirement of lifelong and
life-limiting immunosuppression, liver transplantation should be only per-
formed in patients who are unlikely to recover from ALF. In patients who
recover from ALF with medical support, the liver almost always returns to
normal, both structurally and functionally. Consequently, prevention of
destruction of liver cells in the time-course of ALF and support of liver regen-
eration are the most important goals in management of ALF by molecular
therapies in the future. 
Several molecular mechanisms can initiate liver cell injury and can further
aggravate ongoing damage processes (23). Mitochondria are the prominent
targets for hepatotoxicity of many drugs, leading to impairment of energy
metabolism and intracellular oxidative stress. Once hepatocellular function
is impaired, accumulation of hydrophobic bile acids causes additional cyto-
toxicity. Although drug-induced hepatotoxicity appears to be mediated by
both apoptosis and necrosis, viral infection predominantly induces cell death
of hepatocytes by apoptosis. In contrast to necrosis, apoptosis is a highly
conserved physiological process important in normal development and tissue
homeostasis of multicellular organisms. Apoptosis occurs by two pathways:
a death receptor pathway and a mitochondrial pathway. Signals released
from the cytoplasm and/or from the cell membrane activate a well-characterized
cascade of caspases (cysteine aspartase), which execute apoptotic cell death
(24–27). Receptor-mediated apoptosis, as triggered by the tumor necrosis
factor-R, Fas-, or TNF-related apoptosis-inducing ligand (TRAIL)-receptor
1, has been reported to be involved in the pathogenesis of different liver
diseases like viral hepatitis, ALF, autoimmune hepatitis, ischemia-reperfusion
injury, nonalcoholic steatohepatitis, and toxic liver damage like Wilson’s
disease or bile acid-induced hepatotoxicity (28–33). Therefore, the apoptotic
pathway provides attractive targets for molecular therapy to prevent further
liver damage and provides a condition for successful liver regeneration
in ALF.
Recently, Song et al. (16) and our group (34) reported the therapeutic use of
siRNA in mouse models of ALF. Song et al. used siRNA duplexes targeting the
Fas (CD95) receptor. Three consecutive applications of Fas-siRNA led to an
uptake of siRNA in more than 80% of all hepatocytes resulting in an 8- to 
10-fold downregulation of Fas mRNA expression in the liver. To note, compa-
rable downregulation of Fas had been shown before using ASO (35), however,
this required treating the mice with an approx 14-fold higher amount of anti-
Fas ASO (6 mg/kg body weight for 12 consecutive days). In accordance with
the results from Zhang et al. (35), inhibition of Fas expression by siRNA pro-
tected the hepatocytes against treatment with the Fas-activating antibody Jo-2
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and resulted in significantly increased survival. Remarkably, Fas-siRNA also
conferred protection against ConA-mediated acute liver damage, whereas Fas-
antisense did not.
As it is well established that in addition to FasL, tumor necrosis factor α
and TRAIL are also involved in the pathogenesis of viral hepatitis (36,37),
we reasoned that an essential early downstream mediator of all death recep-
tors would be the most suitable target to achieve the best therapeutic effects
in preclinical animal models of viral hepatitis and ALF. To test this, we
directed siRNA against caspase-8, which is a key downstream effector in
receptor-mediated apoptosis. A single dose of 0.45–0.6 nmol/g body weight
of caspase-8-siRNA resulted in very effective inhibition of caspase-8 expres-
sion in the liver, thus leading to protection against Jo-2-mediated liver damage
or liver damage induced by an adenovirus overexpressing Fas ligand 
(Ad-FasL). With regard to potential clinical applications, it is noteworthy
that caspase-8-siRNA not only prevented acute liver damage but was also
highly effective when delivered into an ongoing ALF. Furthermore, it is of
particular interest that in our study the therapeutic efficiency of caspase-8-
siRNA was shown in acute viral hepatitis that was triggered by wild-type
adenovirus, which better resembles the multiple molecular events in human
acute hepatitis.
2. Materials
2.1. Preparation for Hydrodynamic Tail-Vein Injection in Mice
1. Restraining device for mice.
2. Paper towels, warm water, or alternatively heating lamp.
3. 3-mL Syringe with screw thread, 21- to 27-gauge needle.
4. 0.9% Saline or Ringer’s solution.
5. siRNA duplexes (0.5–1.0 nmol/g body weight).
2.2. Preparation for Portal Vein Injection in Mice
1. Surgery pad for mice.
2. Antiseptic solution.
3. 24-Gauge iv catheter.
4. Gauze.
5. Surgical instruments (scissors, tweezers, and retractors).
6. Ketamine/xylazine, alternatively gas-anesthsia (e.g., isoflurane may be used).
7. Suture material, 4–0.
8. Optional Fibrine/Thrombine adhesive solution (see Subheading 3.).
9. 0.9% Saline or Ringer’s solution.
10. Lipiodol.
11. Microvascular clamps (optional).
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12. Adapter tube and infusion pump (optional).
13. siRNA duplex (0.5–1.0 nmol/g body weight).
3. Methods
3.1. Hydrodynamic/High Volume Tail-Vein Injection 
in Mice (see Note 1)
In principle, any mouse strain can be used for this technique. BALB/c or
other strains with white fur are preferred as visualization and puncture of the
tail vein, especially with bigger needles, is more difficult in black mice.
We prefer to perform standard hydrodynamic tail-vein injection without
anesthesia, as the combination of the high-volume injection together with anes-
thesia can lead to complications in some mice. If anesthesia is used, a gentle
gas-anesthesia (e.g., isoflurane) should be preferred. 
First, the injection solution is prepared. In our hands, best results are
obtained with desalted, lyophilized siRNA duplexes, as siRNA duplexes
lyophilized in annealing buffer can result in higher morbidity of the mice. Most
of the “siRNA-companies” provide siRNA duplexes in a desalted “ready-to-go”
option. The desired amount of siRNA duplex is dissolved in 0.9% saline or
Ringer’s solution. Effective siRNAs should work in a dose of 0.5–1.0 nmol per
gram body weight. The total injection volume can be calculated by dividing the
mouse body weight by 10 (see Note 2).
The mouse is restrained using a suitable restraining device (numerous
Plexiglas versions are available from different manufacturers) and a tail vein is
dilated by application of warm water. Alternatively, some researchers dilate 
the tail vessels by placing the whole mouse under a heating lamp for 10 min. 
A 3-mL syringe with a screw thread is connected to a needle. Needles from 
21- to 27-gauges are suitable. Using syringes without a screw thread can lead
to disconnection during hydrodynamic injection. A tail vein is punctured
approximately midway between the tail tip and middle of the tail. If the first
puncture is not successful, a more proximal puncture site can be tried. After
injecting a small test volume to ensure that the needle is safely placed in the
vein, the whole volume is applied within 4–10 s. Longer injection times will
lead to less effective uptake of siRNA into the liver. Some mice will show heavy
breathing and reduced activity after injection. These symptoms should not last
longer than 30 min.
3.2. Intraportal Delivery of siRNA in Mice
The hydrodynamic tail-vein injection technique leads to high and repro-
ducible siRNA uptake into the liver. It offers the possibility to investigate the
effects of siRNA-mediated gene knockdown in the “target organ” liver in 
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different physiological and pathophysiological settings (see Note 3). However,
a criticism against hydrodynamic tail-vein injection is that it is an experimental
procedure that is not feasible in the clinical situation in humans. Therefore, it is
desirable to have an experimental setting in the mouse model that can resemble
the clinical situation in humans. 
In humans the portal vein can be reached without open surgery by punctur-
ing the jugular vein and placing a catheter from the inferior caval vein through
the liver. Thus, the direct portal vein injection in mice can serve as a model for
this procedure. 
Animals are anesthetized with ketamine/Xxlazine or, if preferred, with gas-
anesthesia (e.g., isoflurane). The abdominal wall is cleaned with antiseptic
solution. A midline ventral incision is made and the abdominal cavity is kept
open with retractors. The bowels are wrapped in saline soaked gauze and placed
sideward of the operation field to obtain a good view on the portal vein. The
desired amount of siRNA (0.5–1.0 nmol) is dissolved in saline or Ringer’s solu-
tion containing 10% lipiodol as an embolizing agent. The use of an embolizing
agent leads to a temporary stasis of the siRNA solution in the liver and, there-
fore, enhances the siRNA uptake into the liver. Alternatively, some researchers
place microvascular clamps on the suprahepatic inferior caval vein during the
injection procedure. This likewise prevents a fast flow-through of the siRNA
solution through the liver. The portal vein is punctured with a 24-gauge iv
catheter. After the plastic catheter is placed in a safe position the needle is
removed. To avoid accidental movement of the catheter during injection, the
portal vein is looped with a 4–0 ligature to tighten the catheter. A total volume
of up to 5% of mouse body weight can be injected within 10 s. Inexperienced
researchers may find it easier to use an adapter tube to connect the catheter to
an infusion-pump instead of injecting free hand. Before removing the needle,
an adhesive solution of Fibrine/Thrombine is spread on the puncture site to pre-
vent bleeding. The abdominal cavity is closed with two separate layers of 4–0
suture material (see Note 4). Fig.  1 shows the inhibition of endogenous expres-
sion of LacZ gene by hydrodynamic-derived siRNAs. 
4. Notes
1. Researchers who are inexperienced with hydrodynamic tail-vein injection in mice
may want to test their technical proficiency by using transgenic mice carrying a
reporter gene like lacZ or green fluorescent protein (GFP). Using this approach
with established siRNA duplexes against lacZ or GFP, the efficiency of siRNA
delivery into the liver can be quantified (see also Fig. 1). Alternatively, Cy-5-
labeled siRNAs can be injected. An easy and precise way to quantify the percent-
age of liver cells with siRNA uptake is to prepare a single-cell suspension of liver
cells using standard collagenase perfusion (38) and subsequently determine the
Cy-5-positive fraction of hepatocytes by flow cytometry. In this context it is
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important to mention that some siRNA duplexes lose their functionality when they
are Cy-5-labeled.
2. To rule out off-target effects of siRNA, two independent siRNAs against every tar-
get should be used.
3. Although siRNA duplexes are effectively delivered to a target organ, the efficiency
of knockdown of a specific gene must be quantified by assaying mRNA and pro-
tein expression.
4. Researchers who want to use the hydrodynamic tail-vein injection technique to
deliver plasmid DNA to the liver are advised to work with supercoiled plasmid
DNA that can be obtained easily by cesium chloride DNA preparations.
5. For experiments that need sustained knockdown of the target gene in the mouse
liver, stability of the respective siRNA in the liver must be tested individually.
Depending on the siRNA duplex, the duration of in vivo knockdown can be vari-
able ranging from 2 d to more than 1 wk.
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